Harmony Biosciences Holdings, Inc. HRMY

Rank #427 · Nasdaq · $2.2B market cap

Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.

Score

65.8

P/E

17.4

P/B

5.57

ROE

32.0%

Op. Margin

33.0%

Debt Ratio

84%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆

Average

P/E 17.4x, P/B 5.57x. Ranks in the top 46% of the universe.

Profitability ★★★★☆

Excellent

ROE 32.0%. Ranks in the top 10% of the universe.

Safety ★★★☆☆

Good

Debt ratio 84%. Ranks in the top 34% of the universe.

Growth ★★★★☆

Excellent

Revenue growth of 32.9% year over year. Ranks in the top 11% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	$0.0B	$-0.1B	$-0.2B	$-0.2B	-2433.8	-49
2021	$0.0B	$-0.1B	$-0.2B	$-0.2B	-2433.8	-136
2022	$0.2B	$0.0B	$-0.0B	$-0.4B	10.6	-58
2023	$0.3B	$0.1B	$0.0B	$0.1B	28.7	279
2024	$0.4B	$0.1B	$0.2B	$0.2B	27.4	185
2025	$0.6B	$0.2B	$0.1B	$0.4B	33.0	84